Organon & Co. misled investors about prioritizing shareholder payments before announcing it slashed quarterly dividends 70% ...

While finasteride’s product information already contains a warning about potential mood changes, the EMA said that packages of 1 mg finasteride tablets will come with a patient card to remind ...

Organon is broadening its presence in dermatology with a deal to acquire Dermavant, a company whose main asset is a commercialized plaque psoriasis drug that could soon expand its approval to ...

In May, I believed that shares of Organon (NYSE:OGN) offered fertile ground for investors. Shares of the business have been pressured since the spin-off from Merck (MRK) amidst elevated debt ...

Listed below are the charts and positions for Organon & Co in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Organon & Co. Sales grew by 19% in the second quarter ...

The European drugs regulator said on Thursday its safety panel has confirmed suicidal thoughts as a side effect of anti-hair-loss drug finasteride and its generic versions, following an EU-wide review ...

Shares of pharmaceutical company Organon (NYSE:OGN) jumped 12.5% in the morning session after the company reported fourth-quarter 2024 results that topped analysts' revenue and EPS expectations.

However, Organon was down 1.4%. Sign up here. Dermavant's Vtama cream, approved by the U.S. Food and Drug Administration in May 2022, treats psoriasis, a common long-term inflammatory skin disease.